Showing 9741-9750 of 21392 results for "".
Seeking Expert Opinions in IgAN Care
https://reachmd.com/programs/clinicians-roundtable/expert-opinions-igan-care/51006/Managing IgA nephropathy (IgAN) is becoming increasingly complex. In this episode, Dr. Anjay Rastogi explains why an expert opinion—not simply a second opinion—can help clinicians confirm diagnoses, optimize treatment decisions, and connect appropriate patients with specialized care and emerging theAdvancing Bone Health: Key Insights from ISO 2026
https://reachmd.com/programs/boning-up-on-osteoporosis/bone-health-iso-2026/61159/From fracture liaison services to menopause care, the 2026 Interdisciplinary Symposium on Osteoporosis (ISO) covered the latest advances and interdisciplinary strategies in bone health. Join Marshall Miller and Ami Patel, Vice President of Science and Education at the Bone Health and Osteoporosis FoManaging RVO: Goals of Early Intervention
https://reachmd.com/programs/eye-on-ocular-health/managing-rvo-goals-of-early-intervention/54487/Retinal vein occlusion (RVO) can lead to significant vision loss when macular edema and ischemic complications are not recognized and treated early. Hear Dr. Michael Javaheri discuss the burden of RVO, key treatment goals, and how newer anti-VEGF therapies may help improve durability while reducingBehind the Breakout: Acne as a Meaningful Side Effect of JAK Inhibitors for IBD
https://reachmd.com/programs/Audioabstracts/jak-inhibitors-acne-side-effect-ibd/49088/As JAK inhibitors become more widely used in treating inflammatory bowel disease (IBD), a new challenge is emerging: acne. That’s why Ryan Quigley spotlights the largest international cohort study to date examining JAK inhibitor-associated acne across more than 2,000 patients. Tune in to learn how fObesity and Asthma: Intersecting Pathways and Real-World Impacts
https://reachmd.com/programs/clinicians-roundtable/obesity-asthma-poor-disease-control/54181/Emerging evidence highlights a complex, bidirectional relationship between obesity and asthma, driven by shared genetics, epigenetic influences, environmental exposures, and metabolic dysfunction. Learn more with Dr. Anne Dixon, who’s a pulmonologist, professor, and the E. L. Amidon Chair of the DepPreventive Care Essentials for Patients with IBD: Reviewing ACG Guideline Updates
https://reachmd.com/programs/gi-insights/program-name/36500/A 2025 update to the American College of Gastroenterology (ACG)'s guideline on preventive care in inflammatory bowel disease (IBD) includes key changes impacting vaccine recommendations, dermatologic screening, and care coordination. Dr. Peter Buch sits down with Dr. Francis Farraye, lead author ofAdvances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
https://reachmd.com/programs/neurofrontiers/program-name/36465/Over the past two decades, Alzheimer’s diagnosis has transformed from uncertain, exclusion-based methods to more accurate detection of disease pathology. With the advent of amyloid PET tracers, cerebrospinal fluid and plasma biomarkers like p-tau 217, and the promise of AI-driven imaging analysis, cThe Far-Reaching Impacts of Psoriasis: Understanding and Mitigating Risks
https://reachmd.com/programs/dermconsult/the-far-reaching-impacts-of-psoriasis-understanding-and-mitigating-risks/32452/Hear how psoriasis can impact a patient’s health beyond their skin and how to best support them to improve outcomes and minimize risks.Genetics in Psoriasis: Impacts on Risk, Comorbidities, and Care
https://reachmd.com/programs/frontlines-psoriasis/genetics-in-psoriasis-impacts-on-risk-comorbidities-and-care/32435/Genetic insights are reshaping how we understand the development and comorbidities of psoriasis, as well as treatment response in patients. Hear Dr. Audrey Bui discuss how genetic variants influence risks for certain conditions, how they may predict response to therapies like methotrexate, ustekinumOne Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
https://reachmd.com/programs/project-oncology/one-year-or-two-dante-trial-explores-immunotherapy-duration-in-metastatic-melanoma/33002/The DANTE phase III trial investigated if stopping anti–PD-1 therapy at one year yields comparable outcomes to longer treatment in metastatic melanoma. Read more about the findings and their potential clinical implications.